Glaukos Co. (NYSE:GKOS) Shares Bought by Lazard Asset Management LLC

Lazard Asset Management LLC raised its position in Glaukos Co. (NYSE:GKOS) by 228.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 13,911 shares of the medical instruments supplier’s stock after acquiring an additional 9,673 shares during the period. Lazard Asset Management LLC’s holdings in Glaukos were worth $2,085,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Focus Partners Wealth purchased a new position in Glaukos in the fourth quarter worth $379,000. Ensign Peak Advisors Inc raised its holdings in Glaukos by 4.4% during the fourth quarter. Ensign Peak Advisors Inc now owns 62,205 shares of the medical instruments supplier’s stock worth $9,327,000 after purchasing an additional 2,631 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Glaukos by 49.6% during the 4th quarter. Deutsche Bank AG now owns 43,859 shares of the medical instruments supplier’s stock worth $6,576,000 after buying an additional 14,540 shares during the last quarter. Divisadero Street Capital Management LP purchased a new stake in shares of Glaukos in the 4th quarter worth about $269,000. Finally, CoreCap Advisors LLC boosted its position in shares of Glaukos by 36.4% in the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Piper Sandler reduced their target price on shares of Glaukos from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Tuesday, April 15th. Stephens reduced their price objective on shares of Glaukos from $140.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, May 2nd. Mizuho reduced their price target on Glaukos from $200.00 to $175.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 16th. Stifel Nicolaus decreased their price objective on Glaukos from $140.00 to $115.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Finally, Truist Financial reiterated a “buy” rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $134.67.

Insider Buying and Selling at Glaukos

In related news, CFO Alex R. Thurman sold 1,520 shares of the firm’s stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at approximately $5,708,568.04. This trade represents a 2.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 5.80% of the company’s stock.

Glaukos Stock Performance

Glaukos stock opened at $95.45 on Friday. Glaukos Co. has a fifty-two week low of $77.10 and a fifty-two week high of $163.71. The firm’s 50 day simple moving average is $93.91 and its 200-day simple moving average is $125.90. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. The company has a market cap of $5.45 billion, a P/E ratio of -33.26 and a beta of 0.83.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.11. The firm had revenue of $106.66 million during the quarter, compared to the consensus estimate of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business’s revenue for the quarter was up 24.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.70) EPS. As a group, equities research analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.